Background
==========

Essential hypertension is a major risk factor for cardiovascular disease and stroke \[[@b1-medscimonit-24-2946]\]. The number of adults with hypertension worldwide is predicted to reach 1.56 billion individuals by 2025 \[[@b2-medscimonit-24-2946]\]. In China, hypertension affects more than one-fourth of the population. Moreover, the prevalence of hypertension has increased during recent decades and it has become a major health problem because treatment awareness and hypertension control rates are extremely low \[[@b3-medscimonit-24-2946]\].

The basic treatment for hypertension is non-pharmacological therapy, and includes weight loss, restricted sodium intake, physical activity, and cessation of smoking and alcohol consumption. However, long-term compliance with non-pharmacological treatment is difficult for most patients. Therefore, anti-hypertensive drugs are the preferred option for treating hypertension \[[@b4-medscimonit-24-2946]\]. However, they are associated with adverse effects such as drug resistance. Therefore, more effective and safe treatment options are urgently required for hypertension patients.

Acupuncture treatment is an ancient Chinese therapy that has played an important role for over 2500 years in the Chinese healthcare system and has now been adopted worldwide. Several systematic reviews have evaluated the efficacy of acupuncture for hypertension \[[@b5-medscimonit-24-2946]--[@b11-medscimonit-24-2946]\]. Recently, some new trials have been published, leading us to conduct a systematic review and meta-analysis of all available randomized controlled trials (RCTs), to evaluate the efficacy and safety of acupuncture therapy for treating essential hypertension.

Material and Methods
====================

Systematic review details
-------------------------

This systematic review was performed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, and was reported in compliance with the PRISMA statement (see [Supplementary Table 1](#s1-medscimonit-24-2946){ref-type="supplementary-material"} for PRISMA checklist) \[[@b12-medscimonit-24-2946]\]. This systematic review has been registered (Reg. No. CRD 42017068032) in PROSPERO (*<https://www.crd.york.ac.uk/prospero/>*) \[[@b13-medscimonit-24-2946]\].

Study search strategy
---------------------

We systematically searched the PUBMED, EMBASE, the Cochrane Library, the Chinese Biomedical Literature Database (CBM), the Chinese National Knowledge Infrastructure (CNKI), and the Wan-fang databases for inclusion on 29 April 2017 with MeSH terms and key words, and without language restrictions. Search strategy terms were (acupuncture OR electroacupuncture OR acupoint) AND (high blood pressure OR hypertension OR blood pressure) AND (randomized controlled trial OR controlled clinical trial OR randomized OR clinical trials). We also checked the reference lists of relevant reviews and the included trials to identify further studies that met the inclusion criteria for this meta-analysis.

Inclusion criteria
------------------

### Types of trials

We included randomized controlled trials (RCTs) and quasi-randomized controlled trials (quasi-RCTs) that were published in formal English or Chinese journals.

### Types of participants

Based on the International Society of Hypertension Guidelines for the Management of Hypertension (1999 World Health Organization) \[[@b14-medscimonit-24-2946]\], essential hypertensive patients were those with a systolic blood pressure (SBP) ≥140 mmHg and/or a diastolic blood pressure (DBP) of ≥90 mmHg. All patients with secondary hypertension caused by an identifiable underlying primary cause were all excluded.

### Types of interventions

Acupuncture therapy included acupuncture or electroacupuncture with or without lifestyle modifications and/or anti-hypertensive drugs. Control groups received sham acupuncture without any treatment or lifestyle modifications or anti-hypertensive drugs.

### Types of outcome measures

Primary outcomes included SBP and DBP changes \[pre-treatment BP -- post-treatment BP\]. Secondary outcomes included the efficacy rates and the adverse events. Efficacy rates were reported as the percentage of the total number of participants that showed reduction of DBP by ≥10 mmHg, or normal DBP (≤90 mmHg), or reduction of SBP by ≥30 mmHg.

Data extraction
---------------

Two reviewers (HC and FES) screened all the literature and extracted data independently using a standardized form. The form was pre-designed for collecting information on trial characteristics, including first author, language, number of patients, mean age of the patients, diagnostic criteria, grades of hypertension, acupuncture treatment, control types, sessions of treatment, treatment course, and outcome measures. We defined the change values of blood pressure as pre-treatment BP minus post-treatment BP and extracted the change means and standard deviations (SD) for continuous outcome. For dichotomous outcome measures, we used rates (the number of events out of total number in the study). If change means and standard deviations were missing, we calculated them according to the formula offered by the *Cochrane Handbook for Systematic Reviews of Interventions* (Version 5.10) (see [Supplementary Figure 1](#s2-medscimonit-24-2946){ref-type="supplementary-material"} for formula). Disagreements were resolved in consultation with the third reviewer (YHG).

Assessment of the reporting quality of the included studies
-----------------------------------------------------------

Overall reporting quality score was evaluated for 30 parameters (items 1--4, 6--19) of the Consolidated Standards of Reporting Trials (CONSORT) \[[@b15-medscimonit-24-2946]\]. The discussion section (items 20--22) was excluded because the items under this section could not be rated. We also excluded the section on other information (items 23--25) because they were not relevant for the methodology of the included studies. The Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA) includes 17 items that are substituted for item 5, 'interventions' in the CONSORT checklist \[[@b16-medscimonit-24-2946]\]. Two reviewers (XDT and WBJ) assessed each item for the included studies independently. Each reported item received 1 point, and any item not clearly presented received 0 points. Disagreements were resolved in consultation with the third reviewer (HC).

Risk of bias assessment
-----------------------

Two reviewers (XDT and WBJ) assessed the risk of bias of the included RCTs using the Cochrane Collaboration's tool for assessing risk of bias \[[@b17-medscimonit-24-2946]\]. Each trial was scored as high, low, or unclear risk for the following 7 domains: (1) random sequence generation (selection bias); (2) allocation concealment (selection bias); (3) blinding of participants and personnel (performance bias); (4) blinding of outcome assessment (detection bias); (5) incomplete outcome data (attrition bias); (6) selective reporting (reporting bias); and (7) any other bias. Disagreements were resolved in consultation with the third reviewer (HC).

Statistical analysis
--------------------

The overall reporting quality of the included studies and the potential differences between the studies from the Chinese journals and English journals were investigated in compliance with the CONSORT and STRICTA statements. The overall scores of the CONSORT and the STRICTA are presented as medians and ranges, and data from each individual item are presented as frequencies. The difference between overall scores of different journals was assessed by the Mann-Whitney U test. Pearson's chi-square test was used when the sample size was more than 40 and Fisher's exact test was used when sample size was less than 40 for assessing the reporting difference of each individual item between the different journals. Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS) V.19.0 (SPSS Inc, Chicago, Illinois, USA).

Meta-analyses for acupuncture and electroacupuncture were done separately. Continuous data are presented as mean differences (MDs) with 95% confidence interval (CI) and data from studies were pooled using the inverse variance method. Dichotomous data are presented as relative risk (RR) with 95% CI and pooled using Mantel-Haenszel method. We also calculated the required information size based on the standard method \[[@b18-medscimonit-24-2946],[@b19-medscimonit-24-2946]\]. Statistical heterogeneity across trials was assessed by the Cochran Q test (P\<0.1 for statistical significance) and quantified by the*I^2^* statistic. Following the*Cochrane Handbook for Systematic Reviews of Interventions* (Version 5.10), we defined *I^2^* \>50% as indicating significant heterogeneity. Heterogeneous data were pooled using the random-effects model. We performed subgroup analysis based on the classes of anti-hypertensive drugs such as calcium channel blockers (CCB), β-receptor antagonists, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARB). Moreover, in order to establish robust primary outcomes, we also performed sensitivity analysis for the primary outcomes. Publication bias was evaluated by visually inspecting a funnel plot. Meta-analysis was performed using RevMan 5.3 software.

Results
=======

Study selection
---------------

[Figure 1](#f1-medscimonit-24-2946){ref-type="fig"} provides a flow chart summarizing the study selection process based on PRISMA guidelines. The initial search yielded 1146 records. After removing duplicate records, screening the titles and abstracts, and doing full text reviews, 30 trials were included in the meta-analysis \[[@b20-medscimonit-24-2946]--[@b49-medscimonit-24-2946]\].

Characteristics of the included studies
---------------------------------------

Characteristics of the included trials are summarized in [Table 1](#t1-medscimonit-24-2946){ref-type="table"}. The 28 RCTs and 2 qusi-RCTs evaluated a total of 2107 patients (range: 28 to 160 patients per trial) and were published between 2000 and 2016. Six of the included studies were published in English \[[@b25-medscimonit-24-2946]--[@b27-medscimonit-24-2946],[@b29-medscimonit-24-2946],[@b30-medscimonit-24-2946],[@b49-medscimonit-24-2946]\] and the remaining 24 studies were published in Chinese \[[@b20-medscimonit-24-2946]--[@b24-medscimonit-24-2946],[@b28-medscimonit-24-2946],[@b31-medscimonit-24-2946]--[@b42-medscimonit-24-2946],[@b47-medscimonit-24-2946],[@b48-medscimonit-24-2946]\]. Four studies reported adverse effects \[[@b22-medscimonit-24-2946],[@b26-medscimonit-24-2946],[@b40-medscimonit-24-2946],[@b41-medscimonit-24-2946]\], 5 studies reported no adverse effects \[[@b25-medscimonit-24-2946],[@b27-medscimonit-24-2946],[@b29-medscimonit-24-2946],[@b30-medscimonit-24-2946],[@b38-medscimonit-24-2946]\], and the remaining 21 studies did not report any information on adverse effects. Twenty-eight of the 30 studies defined the criteria for hypertension as a systolic blood pressure (SBP) ≥140mmHg or diastolic blood pressure (DBP) ≥90 mmHg \[[@b22-medscimonit-24-2946]--[@b29-medscimonit-24-2946],[@b31-medscimonit-24-2946]--[@b48-medscimonit-24-2946]\]. Liu et al. \[[@b30-medscimonit-24-2946]\] included hypertension patients with SBP ranging from 120--159 mmHg or DBP ranging from 80--99 mmHg. Yin et al. \[[@b49-medscimonit-24-2946]\] included patients with SBP ranging from 120 to 180 mmHg or DBP 80 to 100 mmHg.

We analyzed the therapeutic outcomes of acupuncture or electroacupuncture with or without lifestyle modifications or anti-hypertensive drugs. The 5 most frequently used acu-points were LI11 (quchi; 18 studies), LR3 (taichong; 15 studies), GB20 (fengchi; 12 studies), ST36 (zusanli; 9 studies), and DU20 (baihui; 7 studies). Control groups included untreated patients and patients undergoing treatment by lifestyle modifications or anti-hypertensive drugs. The median course of the included studies was 28 days (range: 14--56).

Reporting quality of the included studies
-----------------------------------------

We evaluated the reporting quality of the included studies according to CONSORT and STRICTA guidelines. The CONSORT median quality score was 10 (range: 4--29, [Table 2](#t2-medscimonit-24-2946){ref-type="table"}), Based on the CONSORT, Chinese journals (median score: 10; range: 6--17) and English journals (median score: 9; range: 4--29) had similar reporting quality (*P*=0.875). However, consideration of individual items shows that the quality of English journals is better than Chinese journals for reporting items 1a, 2b, 8b, 9, 11a, 13b, 15, and 19 (all *P*\<0.05; [Table 3](#t3-medscimonit-24-2946){ref-type="table"}).

The STRICTA median score was 11 (range: 7--11, [Table 2](#t2-medscimonit-24-2946){ref-type="table"}), and using STRICTA, English journals (median score: 12; range: 11--17) have a better reporting quality (P=0.03) than Chinese journals (median score: 11; range: 7--12). Similarly, the STRICTA report shows that the quality of English journals is better than Chinese journals for items 1b, 1c, 4a, and 6a (all *P*\<0.05; [Table 4](#t4-medscimonit-24-2946){ref-type="table"}).

Risk of bias of the included studies
------------------------------------

Most included studies had poor methodological quality because they lacked sufficient information to assess special items by the Cochrane risk of bias tool ([Figure 2](#f2-medscimonit-24-2946){ref-type="fig"}). Two trials were quasi-RCTs \[[@b35-medscimonit-24-2946],[@b45-medscimonit-24-2946]\], in which the patients were randomized according to even and odd numbers. Twenty-one trials generated a randomized sequence for patients by using a random number table or software \[[@b20-medscimonit-24-2946]--[@b23-medscimonit-24-2946],[@b25-medscimonit-24-2946],[@b27-medscimonit-24-2946],[@b28-medscimonit-24-2946],[@b30-medscimonit-24-2946]--[@b33-medscimonit-24-2946],[@b36-medscimonit-24-2946],[@b38-medscimonit-24-2946]--[@b40-medscimonit-24-2946],[@b42-medscimonit-24-2946],[@b44-medscimonit-24-2946],[@b47-medscimonit-24-2946]--[@b49-medscimonit-24-2946]\]. The remaining 7 studies did not indicate how random assignments were made. Appropriate allocation concealment was reported in only 5 trials, all published in English \[[@b25-medscimonit-24-2946],[@b27-medscimonit-24-2946],[@b29-medscimonit-24-2946],[@b30-medscimonit-24-2946],[@b49-medscimonit-24-2946]\]. Adequate blinding of patients and the doctors was not reported by any of the 30 trials. Blinding of the outcome assessment was mentioned in only 3 trials \[[@b25-medscimonit-24-2946],[@b30-medscimonit-24-2946],[@b44-medscimonit-24-2946]\]. Only 1 study used intention-to-treat analysis \[[@b27-medscimonit-24-2946]\]. Eight trials reported dropouts \[[@b27-medscimonit-24-2946],[@b29-medscimonit-24-2946]--[@b31-medscimonit-24-2946],[@b34-medscimonit-24-2946],[@b38-medscimonit-24-2946],[@b41-medscimonit-24-2946],[@b48-medscimonit-24-2946]\]. Selective reporting is unknown for any of the included studies, since we have no access to the study protocol.

Analyzing the effects of different interventions
------------------------------------------------

We performed the following 8 comparisons based on different types of interventions evaluated in the included studies: (1) acupuncture *vs.* anti-hypertensive drugs; (2) acupuncture *vs.* no treatment; (3) acupuncture *vs.* sham acupuncture; (4) acupuncture plus lifestyle modifications *vs.* lifestyle modifications; (5) acupuncture plus anti-hypertensive drugs *vs.* anti-hypertensive drugs; (6) acupuncture plus anti-hypertensive drugs *vs.* sham acupuncture plus anti-hypertensive drugs; (7) electroacupuncture *vs.* anti-hypertensive drugs; and (8) electroacupuncture plus anti-hypertensive drugs *vs.* anti-hypertensive drugs. The pooled effect estimates for all these comparisons are shown in [Figures 3](#f3-medscimonit-24-2946){ref-type="fig"}[](#f4-medscimonit-24-2946){ref-type="fig"}--[5](#f5-medscimonit-24-2946){ref-type="fig"}.

### 1. Acupuncture vs. anti-hypertensive drugs

Eight studies with 541 patients reported SBP and DBP compared acupuncture and anti-hypertensive drug treatments \[[@b20-medscimonit-24-2946],[@b22-medscimonit-24-2946],[@b24-medscimonit-24-2946],[@b35-medscimonit-24-2946],[@b39-medscimonit-24-2946]--[@b41-medscimonit-24-2946],[@b43-medscimonit-24-2946]\]. SBP and DBP changes were similar for acupuncture and anti-hypertensive drug treatments \[SBP: MD=1.4 mmHg (95% CI: −1.32 to 4.12), *I^2^*=57%; DBP: MD=2.04 mmHg (95% CI: −0.59 to 4.67), *I^2^*=83%\].

Nine studies with 517 patients reported efficacy rates of acupuncture and anti-hypertensive drug treatments \[[@b20-medscimonit-24-2946],[@b22-medscimonit-24-2946]--[@b24-medscimonit-24-2946],[@b35-medscimonit-24-2946],[@b39-medscimonit-24-2946]--[@b41-medscimonit-24-2946],[@b46-medscimonit-24-2946]\]. The efficacy rates of both these treatments were similar \[RR=1.12 (95% CI: 0.98 to 1.28),*I^2^*=78%\].

### 2. Acupuncture vs. no treatment

Only 1 study with 30 patients reported SBP and DBP in patients treated with acupuncture compared to an untreated control group \[[@b30-medscimonit-24-2946]\]. No differences were observed between treatments in SBP change \[SBP: MD=5.2 mmHg (95% CI: −2.99 to 13.39)\]. However, DBP changes were greater in patients treated with acupuncture than in untreated patients \[DBP: MD=6.1mmHg (95% CI: 1.27 to 10.93)\].

### 3. Acupuncture vs. sham acupuncture

Three studies with 106 patients reported SBP and DBP for acupuncture versus sham acupuncture treatments \[[@b25-medscimonit-24-2946],[@b48-medscimonit-24-2946],[@b49-medscimonit-24-2946]\]. The SBP and DBP changes were similar for both acupuncture and sham acupuncture treatments \[SBP: MD=1.59 mmHg (95% CI: −4.63 to 7.8 mmHg), *I^2^*=65%; DBP: MD=−0.01 mmHg (95% CI: −2.59 to 2.57), *I^2^*=15%\].

### 4. Acupuncture plus lifestyle modifications vs. lifestyle modifications

Three studies with 246 patients compared acupuncture plus lifestyle modifications and lifestyle modifications alone \[[@b34-medscimonit-24-2946],[@b38-medscimonit-24-2946],[@b49-medscimonit-24-2946]\]. Two of the three studies (n=187) also reported the efficacy rate of acupuncture plus lifestyle medications and lifestyle modifications alone \[[@b34-medscimonit-24-2946],[@b38-medscimonit-24-2946]\]. SBP and DBP changes, as well as efficacy rate, were greater in the combined therapy than in lifestyle modifications alone \[SBP: MD=10.38 mmHg (95% CI: 6.72 to 14.04), *I^2^*=86%; DBP: MD=5.74 mmHg (95% CI: 1.94 to 9.54), *I^2^*=91%; RR: 1.2 (95% CI: 1.05 to 1.36), *I^2^*=0%\]. This suggests a synergy occurs between acupuncture and lifestyle modification.

### 5. Acupuncture plus anti-hypertensive drugs vs. anti-hypertensive drugs

Five studies with 365 patients compared treatments of acupuncture plus anti-hypertensive drugs *vs.* anti-hypertensive drugs alone for blood pressure effects \[[@b28-medscimonit-24-2946],[@b31-medscimonit-24-2946],[@b33-medscimonit-24-2946],[@b44-medscimonit-24-2946],[@b45-medscimonit-24-2946]\], and 7 studies with 517 patients reported efficacy rates for these 2 treatments \[[@b21-medscimonit-24-2946],[@b26-medscimonit-24-2946],[@b28-medscimonit-24-2946],[@b31-medscimonit-24-2946],[@b33-medscimonit-24-2946],[@b44-medscimonit-24-2946],[@b45-medscimonit-24-2946]\]. Both SBP and DBP changes, as well as efficacy rates, were higher in acupuncture plus anti-hypertensive drug treatment than in treatment with anti-hypertensive drugs alone \[SBP: MD=9.8 mmHg (95% CI: 2.95 to 16.65), *I^2^*=94%; DBP: MD=7.82 mmHg (95% CI: 4.67 to 10.96), *I^2^*=79%; RR=1.17 (95% CI: 1.08 to 1.27),*I^2^*=0%\].

### 6. Acupuncture plus anti-hypertensive drugs vs. sham acupuncture plus anti-hypertensive drugs

Two studies with 170 patients compared the treatments of acupuncture plus anti-hypertensive drugs and sham acupuncture plus anti-hypertensive drugs treatments on blood pressure \[[@b27-medscimonit-24-2946],[@b49-medscimonit-24-2946]\]. Changes in SBP and DBP differed between these treatment groups (SBP: MD=8.82 mmHg) (95% CI; 5.1 to 12.54),*I^2^*=35%; DBP: MD=4.44 mmHg (95% CI: 1.7 to 7.19) *I^2^*=36%)

### 7. Electro-acupuncture vs. anti-hypertensive drugs

Three studies with 200 patients reported SBP and DBP changes with electroacupuncture *vs.* anti-hypertensive drugs \[[@b32-medscimonit-24-2946],[@b36-medscimonit-24-2946],[@b42-medscimonit-24-2946]\] and two (n=99) reported on efficacy rate \[[@b32-medscimonit-24-2946],[@b36-medscimonit-24-2946]\]. Electroacupuncture and anti-hypertensive drugs treatments showed similar SBP and DBP magnitude changes and efficacy rates \[SBP: MD=1.63 mmHg (95% CI: −3.25 to 6.52), *I^2^*=57%; DBP: MD=−1.98 mmHg (95% CI: −4.85 to 0.62), *I^2^*=31%; RR=0.94 (95% CI: 0.76 to 1.16), *I^2^*=0%\].

### 8. Electro-acupuncture plus anti-hypertensive drugs vs. anti-hypertensive drugs

Only 1 study with 59 patients compared treatment effects of electro-acupuncture plus Lotensin *vs.* Lotensin alone on blood pressure \[[@b37-medscimonit-24-2946]\]. SBP changes were greater in the combined therapy than with lotensin alone \[SBP: MD=9.12 mmHg (95% CI: 3.96 to 14.28)\]. However, DBP changes were similar in treatment groups \[DBP: MD=4.46 mmHg (95% CI: −0.25 to 9.17)\].

Subgroup analysis
-----------------

Clinical heterogeneity is attributed in part to the use of different classes of anti-hypertensive drugs; drugs used included CCB, β-receptor antagonists, ACEI, and ARB. To control for this heterogeneity, we performed subgroup analyses of blood pressure for different classes of anti-hypertensive drugs. Pooled data indicated that DBP changes are similar in acupuncture and anti-hypertensive drug treatments ([Figures 6](#f6-medscimonit-24-2946){ref-type="fig"}, [7](#f7-medscimonit-24-2946){ref-type="fig"}). One study \[[@b22-medscimonit-24-2946]\] showed that acupuncture lowered SBP better than ARB \[SBP: MD=11.15 mmHg (95% CI: 3.68 to 18.62\]. Pooled result from 4 studies \[[@b31-medscimonit-24-2946],[@b33-medscimonit-24-2946],[@b44-medscimonit-24-2946],[@b45-medscimonit-24-2946]\] showed that SBP and DBP changes were also higher in the acupuncture plus CCB treatment than with CCB treatment alone \[SBP: MD=10.83 mmHg (95% CI: 3.38 to 18.27),*I^2^*=95%; DBP: MD=8.69 mmHg (95% CI: 5.32 to 12.07), *I^2^*=81%\].

Sensitivity analysis for the primary outcomes
---------------------------------------------

We did a sensitivity analysis for SBP and DBP and efficacy rate by omitting studies one at a time. Meta-analysis results for reduced data were similar to the original results ([Tables 5](#t5-medscimonit-24-2946){ref-type="table"}[](#t6-medscimonit-24-2946){ref-type="table"}--[7](#t7-medscimonit-24-2946){ref-type="table"}), suggesting that the pooled data results are robust.

Safety evaluation
-----------------

Nine of the included studies reported adverse events during the trial \[[@b22-medscimonit-24-2946],[@b25-medscimonit-24-2946]--[@b27-medscimonit-24-2946],[@b29-medscimonit-24-2946],[@b30-medscimonit-24-2946],[@b38-medscimonit-24-2946],[@b40-medscimonit-24-2946],[@b41-medscimonit-24-2946]\]. No study reported subject dropouts due to adverse events. In 4 studies \[[@b22-medscimonit-24-2946],[@b26-medscimonit-24-2946],[@b40-medscimonit-24-2946],[@b41-medscimonit-24-2946]\], adverse events such as headache, syncope, dizziness, pain, cough, and bleeding were reported in the treatment group. The adverse effects of headache, dizziness, cough, and hypotension were reported in the control group \[[@b22-medscimonit-24-2946],[@b26-medscimonit-24-2946],[@b40-medscimonit-24-2946],[@b41-medscimonit-24-2946]\]. The incidence of the adverse events was similar for both groups of patients \[RR=0.48 (95% CI: 0.14 to 1.61), *I^2^*=52%\].

Publication bias
----------------

A funnel plot analysis revealed strong asymmetry ([Figure 8](#f8-medscimonit-24-2946){ref-type="fig"}), suggesting potential publication bias, probably due to the small sample sizes of the included studies.

Discussion
==========

This systematic review of 28 RCTs and 2 quasi-RCTs showed that acupuncture plus anti-hypertensive drug treatment was better than anti-hypertensive drugs alone or sham acupuncture plus anti-hypertensive drugs, based on change in SBP and DBP. These results suggest that acupuncture enhances the beneficial effects of anti-hypertensive drugs.

DBP changes were greater in patients treated with acupuncture than in untreated patients. Moreover, SBP changes were greater in patients treated with electro-acupuncture plus Lotensin than in Lotensin alone. However, since only 1 study was available to assess both of these comparisons \[[@b30-medscimonit-24-2946]\], these findings are preliminary and need further evidence.

Our findings also show that lowering of blood pressure is similar in treatments with acupuncture alone and with anti-hypertensive drugs alone. Blood pressure changes are similar for sham acupuncture and acupuncture treatments. Moreover, pooled data from 3 studies showed that blood pressure changes are similar for treatments with electro-acupuncture and anti-hypertensive drugs alone \[[@b32-medscimonit-24-2946],[@b36-medscimonit-24-2946],[@b42-medscimonit-24-2946]\]. These results showed that acupuncture therapy alone was not sufficient for treating hypertension. However, there is significant heterogeneity among the studies; therefore, the quality of the results is low.

Subgroup analysis for different classes of anti-hypertensive drugs reveals that SBP changes are greater for acupuncture treatment than treatment with ARB and β-receptor antagonists. No significant differences are present in DBP changes between acupuncture and the different classes of anti-hypertensive drugs. However, the subgroup analysis reveals that acupuncture combined with CCB was more effective than CCB alone. These results are inconsistent and the data are insufficient to draw any conclusions.

We found that the reporting quality of the included studies was very low, especially for the Chinese journals. STRICTA statement analysis shows that the reporting quality of English journals is better than in Chinese journals. CONSORT statement analysis found no difference between the 2 groups overall, but the English journals had better reporting of the methodological section of the CONSORT statement (sequence generation, allocation, blinding, baseline data, and harms/adverse effects) than Chinese journals. Failure to report details of design methodology is a potential source of increased heterogeneity in the included studies. Therefore, these issues affected the analyses of acupuncture therapy for hypertension.

We also collected the published systematic reviews on the topic ([Tables 8](#t8-medscimonit-24-2946){ref-type="table"}, [9](#t9-medscimonit-24-2946){ref-type="table"}). Compared with these systematic reviews, the current systematic review updates the latest evidence, and provides subgroup analysis based on the different classes of anti-hypertensive drugs, which generates most of the clinical heterogeneity. Nonetheless, several limitations to our meta-analysis exist. First, substantial heterogeneity exists among the included studies. In clinics, the methods of acupuncture and selection of the acu-points may vary because the treatment is based on the syndrome differentiation of Traditional Chinese Medicine, which leads to heterogeneity. Moreover, reporting quality of the included studies is low, especially in the methodology section of the study design, which can also be a source for heterogeneity. Second, a lack of translators meant we could only include Chinese and English studies, which leads to a selection bias. Third, sample sizes of the included studies, especially in Chinese trials, are small and the wide confidence intervals indicate high variability.

Therefore, the precise effects of acupuncture therapy for treating hypertension remain uncertain given the high overall risk of bias in our included studies. Thus, well-designed and large-sized RCTs are needed.

Conclusions
===========

In conclusion, this review provides evidence that acupuncture enhances the therapeutic effects of anti-hypertensive drugs. However, the benefits and the safety of acupuncture therapy for treating hypertension are still unclear because of methodology flaws and low reporting quality of published studies. High-quality RCTs with larger sample sizes are required to better assess the outcomes of acupuncture therapy as treatment for hypertension.
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  Data items                           11   List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made                                                                                                                                                                         5
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                       5
  Summary measures                     13   State the principal summary measures (e.g., risk ratio, difference in means)                                                                                                                                                                                                                                 6
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis                                                                                                                                                         6
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies)                                                                                                                                                                  5--6
  Additional analyses                  16   Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified                                                                                                                                                              6
  **RESULTS**                                                                                                                                                                                                                                                                                                                                            
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram                                                                                                                                               6--7
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  Additional analysis                  23   Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[see Item 16\])                                                                                                                                                                                       10
  **DISCUSSION**                                                                                                                                                                                                                                                                                                                                         
  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers)                                                                                                                          11--12
  Limitations                          25   Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias)                                                                                                                                                 12--13
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research                                                                                                                                                                                       13
  **FUNDING**                                                                                                                                                                                                                                                                                                                                            
  Funding                              27   Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review                                                                                                                                                                    1

###### 

The formula for calculating the missing change-from-baseline standard deviation.

**Conflicts of interest**

None.

**Source of support:** This study was support both by the National Natural Science Foundation of China (Grant No. 81674063) and the Traditional Chinese Medicine Science and Technology Project funded by the Bureau of Traditional Chinese Medicine of Jiangsu province (Grant No. YB2015006)

![Flow chart of randomized controlled trial selection (based on PRISMA).](medscimonit-24-2946-g001){#f1-medscimonit-24-2946}

![Risk of bias graph of the included trials. (**A**) Summary of the risk of bias in 7 domains in the 30 RCTs. (**B**) Graphical representation of the overall risk of bias in the 7 domains. Green, yellow and red represent low, unclear and high risk of bias. Length of the rectangles (green, yellow or red) show the percentage of studies with low, unclear, or high risk of bias for the 7 domains analyzed.](medscimonit-24-2946-g002){#f2-medscimonit-24-2946}

![Forest plot of SBP magnitude changes in all 30 trials.](medscimonit-24-2946-g003){#f3-medscimonit-24-2946}

![Forest plot of DBP magnitude changes in all 30 trials.](medscimonit-24-2946-g004){#f4-medscimonit-24-2946}

![Forest plot of the efficacy rate of acupuncture therapy in all trials.](medscimonit-24-2946-g005){#f5-medscimonit-24-2946}

![Subgroup analyses of (A) SBP and (B) DBP magnitude changes in patients that underwent acupuncture or anti-hypertensive drug therapies.](medscimonit-24-2946-g006){#f6-medscimonit-24-2946}

![Subgroup analyses of (**A**) SBP and (**B**) DBP magnitude changes in patients that underwent therapy with acupuncture plus anti-hypertensive drugs or anti-hypertensive drugs alone.](medscimonit-24-2946-g007){#f7-medscimonit-24-2946}

![Funnel plot of (**A**) SBP, (**B**) DBP, and (**C**) efficacy rate in all trials.](medscimonit-24-2946-g008){#f8-medscimonit-24-2946}

###### 

Characteristics of included studies.

  Study ID                      Language   Mean age (T/C)             Gender (Male/Female)   [\*](#tfn2-medscimonit-24-2946){ref-type="table-fn"}Included criteria   Hypertension grades   Intervention                                        No. of patients evaluated                         Course   [\#](#tfn3-medscimonit-24-2946){ref-type="table-fn"}Outcome                  
  ----------------------------- ---------- -------------------------- ---------------------- ----------------------------------------------------------------------- --------------------- --------------------------------------------------- ------------------------------------------------- -------- ------------------------------------------------------------- -------------- ---------
  Chen BG et al., 2006          Chinese    54.75±7.12/51.7210.38      41/19                  1                                                                       1, 2                  AC (30 mins a day)                                  Metroprolol (100 mg per day)                      30       30                                                            4 weeks        1, 2, 3
  Chen J et al., 2010           Chinese    48.2±7.2/50.5± 8.4         31/29                  1                                                                       1                     AC (30 mins a day) plus felodipine (5 mg per day)   Felodipine (5 mg per day)                         30       30                                                            15 days        3
  Chen NY et al., 2010          Chinese    61.3±8.0/62.0± 7.1         41/39                  1                                                                       Not reported          AC (30 mins a day)                                  Diovan (80 mg per day)                            40       40                                                            30 days        1, 3, 4
  Chen Q et al., 2011           Chinese    59±8/59± 8                 29/31                  1                                                                       1, 2                  AC (30 mins a day)                                  Metroprolol (100 mg per day)                      30       30                                                            30 days        3
  Chen YF et al., 2000          Chinese    63.57±8.08/65.20± 8.86     38/32                  1                                                                       2                     AC (30 mins a day)                                  Nifedipine (10--20 mg tid)                        35       35                                                            2 weeks        1, 3
  Choi WJ et al., 2015          English    48.04±6.13/46.20±9.26      Not reported           1                                                                       Not reported          AC (20 mins every treatment, 4 times totally)       SA                                                25       25                                                            2 weeks        2, 4
  Cui JK et al., 2013           English    56.7±8.9/54.7±8.1          55/37                  1                                                                       Not reported          AC (once a day except Sunday) plus irbesartan       Irbesartan (150 mg per day)                       46       46                                                            4 weeks        3, 4
  Flachskampf FA et al., 2007   English    58.8±8.2/58.0±7.9          66/74                  1                                                                       1, 2                  AC (30 mins; 22 sessions)                           SA                                                83       77                                                            6 weeks        1, 2, 4
  Huang F et al., 2007          Chinese    56.51±6.28/58.12±6.15      27/33                  1                                                                       1, 2                  AC (30 mins a day) plus captopril (25 mg tid)       Captopril (25 mg tid)                             30       30                                                            4 weeks        1, 3
  Kim HM et al., 2012           English    52.08±8.69/52.38±10.3      16/12                  1                                                                       1                     AC (20 mins, twice a week)                          SA                                                12       16                                                            8 weeks        1, 2
  Liu Y et al., 2015            English    49.4±8.4/53.4±8.2          7/24                   2                                                                       1,2                   AC (30 mins, twice a week)                          No treatment                                      15       15                                                            8 weeks        2
  Luo H et al., 2015            Chinese    45--75 (range)             66/34                  1                                                                       2                     AC (30 mins a day) plus felodipine (5mg)            Felodipine (5 mg)                                 44       46                                                            20 days        1, 3
  Ma ZY et al., 2011            Chinese    66.39±5.47/64.58±7.13      47/33                  1                                                                       1,2                   EA (10 mins a day)                                  Nicardipine (20 mg tid)                           40       40                                                            15 days        1, 3
  Shen ZK et al., 2007          Chinese    32±8.24/21±7.31            31/19                  1                                                                       Not reported          AC (30 mins a day) plus nifedipine (20 mg bid)      Nifedipine (20mg bid)                             25       25                                                            20 days        1, 2, 3
  Sun J et al., 2009            Chinese    47.23±5.66/48.42±6.13      48/39                  1                                                                       1                     AC (30 mins a day)                                  lifestyle                                         44       43                                                            Not reported   2
  Tian L et al., 2008           Chinese    59.17±3.16/59±3.01         33/27                  1                                                                       1,2                   AC (30 mins a day)                                  Levamlodipine (2.5 mg a day)                      30       30                                                            30 days        1, 2, 3
  Yin C et al., 2007            English    52/54                      9/21                   3                                                                       1,2                   AC plus antihypertensive                            SA plus antihypertensive                          15       15                                                            8 weeks        1
  Wan WJ et al., 2009           Chinese    63.72±8.23/65.24±6.41      36/24                  1                                                                       1,2                   AC (10mins a day)                                   nicardipine (20 mg tid)                           30       30                                                            15 days        1,3
  Wang C et al., 2006           Chinese    25--60(range)              34/25                  1                                                                       Not reported          EA (30 mins a day)                                  Lotensin (10 mg a day)                            30       29                                                            8 weeks        1,3
  Wu XM et al., 2015            Chinese    49\. 10±8. 7/48. 08±8. 8   52/47                  1                                                                       1,2                   AC (10 mins a day)                                  lifestyle                                         50       49                                                            4 weeks        1, 2, 3
  Wu YR et al., 2011            Chinese    54.75±7.10/51.72±10.3      70/50                  1                                                                       1,2                   AC (30 mins a day)                                  Metroprolol (100 mg a day)                        60       60                                                            20 days        1, 3
  Xie B et al., 2014            Chinese    56±11/53±10                30/30                  1                                                                       Not reported          AC (30 mins a day)                                  Captopril (25 mg tid)                             30       30                                                            3 weeks        1, 3
  Xing H et al., 2016           Chinese    61.83±9.10/57.14±9.33      35/28                  1                                                                       1,2                   AC (30 mins a day)                                  Captopril (25 mg tid)                             31       32                                                            4 weeks        1, 3
  Yang DH et al., 2010          Chinese    40.4±5.2/41.7±4.2          37/23                  1                                                                       1,2                   EA (30 mins a day)                                  Captopril (25 mg tid)                             30       30                                                            2 weeks        1, 2, 3
  Zhao DJ et al., 2003          Chinese    40.3±11.4/46.1±14.2        37/23                  1                                                                       1,2                   AC plus lifesytle                                   Lifestyle                                         30       30                                                            40 days        1
  Zhang Y et al., 2012          Chinese    42--46 (range)             Not reported           1                                                                       Not reported          AC (30 mins a day)                                  Captopril (25 mg tid)                             14       14                                                            8 weeks        1
  Zhang YB et al., 2011         Chinese    53.62±9.83/52.16±10.04     53/27                  1                                                                       Not reported          AC (20 mins a day)                                  Amlodipine (2.5 mg a day)                         45       35                                                            4 weeks        1, 3
  Zhang YL et al., 2005         Chinese    63.60±8.20/65.20±8.00      47/28                  1                                                                       Not reported          AC (30 mins a day) plus nifedipine (10mg tid)       Nifedipine (10 mg tid)                            45       30                                                            20 days        1, 3
  Zhang ZH et al., 2004         Chinese    56.5/55.5                  42/18                  1                                                                       1,2                   AC (30 mins a day)                                  Compounds of Reserpine and Hydrochlorothiazidec   30       30                                                            15 days        3
  Zheng Y et al., 2016          English    56.53±7.52/56.73±4.91      8/22                   1                                                                       1,2                   AC (30 mins a day except weekends)                  SA                                                15       15                                                            2 weeks        1

T -- treatment; C -- control; mins -- minutes; AC -- acupuncture; SA -- sham acupuncture; EA -- electro acupuncture; SBP -- systolic blood pressure; DBP -- diastolic blood pressure.

Included criteria: (1) SBP: ≥140 mmHg or DBP: ≥90 mmHg; (2) SBP: 120--159 mmHg or DBP: 80--99 mmHg; (3) SBP: 120--180 mmHg and DBP: 80--100 mmHg

Outcomes: (1) Blood pressure after intervention; (2) Changes in magnitude of blood pressure after intervention; (3) Efficacy rate; (4) Adverse effects.

###### 

Overall score of the CONSORT and STRICTA reporting quality of the included studies (N=30; 24 studies from Chinese journals; 6 studies from English journals).

  ------------------------------------------------------------------------------------------------------------
  Journals                  CONSORT\         STRICTA\
                            Median (range)   Median (range)
  ------------------------- ---------------- -----------------------------------------------------------------
  Chinese journals (N=24)   10 (6--17)       11 (7--12)

  English journals (N=6)    9 (4--29)        12 (11--17)[\*](#tfn4-medscimonit-24-2946){ref-type="table-fn"}

  All journals (N=30)       10 (4--29)       11 (7--17)
  ------------------------------------------------------------------------------------------------------------

Indicate a significant difference with the studies published in Chinese journals.

###### 

CONSORT assessments of the reporting characteristics of the included studies (N=30; 24 studies from Chinese journals; 6 studies from English journals).

  Section/ topic                                         Item                                                                                                                     Description                                                                                                                                                                                        Positive studies   Positive Chinese journals                                     Positive English journals
  ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ------------------------------------------------------------- -------------------------------------------------------------
  Title and Abstract                                     1a                                                                                                                       Identifying randomized trial in the title                                                                                                                                                          4 (13%)            0 (0)                                                         4 (67%)[\*](#tfn5-medscimonit-24-2946){ref-type="table-fn"}
  1b                                                     Structured summary of trial design, methods, results, and conclusions; for specific guidance see CONSORT for Abstracts   28 (93)                                                                                                                                                                                            22 (92)            6 (100)                                                       
  Background and objectives                              2a                                                                                                                       Scientific background and explanation of rationale                                                                                                                                                 23 (77)            17 (71)                                                       6 (100)
  2b                                                     Specific objectives or hypotheses                                                                                        12 (40)                                                                                                                                                                                            6 (25)             6 (100)[\*](#tfn5-medscimonit-24-2946){ref-type="table-fn"}   
  Trial design                                           3a                                                                                                                       Description of trial design (e.g., parallel, factorial) including allocation ratio                                                                                                                 29 (97)            23 (96)                                                       6 (100)
  3b                                                     Important changes to methods after trial commencement (e.g. eligibility criteria), with reasons                          0                                                                                                                                                                                                  0 (0)              0 (0)                                                         
  Participants                                           4a                                                                                                                       Eligibility criteria for participants                                                                                                                                                              29 (97%)           23 (96)                                                       6 (100)
  4b                                                     Settings and locations where the data were collected                                                                     24 (80%)                                                                                                                                                                                           18 (75)            6 (100)                                                       
  Outcomes                                               6a                                                                                                                       Definition of pre-specified primary and secondary outcome measures, including how and when they were assessed                                                                                      28 (93)            22 (92)                                                       6 (100)
  6b                                                     Reasoning of any changes to trial outcomes after the trial commenced                                                     0 (0)                                                                                                                                                                                              0 (0)              0 (0)                                                         
  Sample size                                            7a                                                                                                                       Protocol of determining sample size                                                                                                                                                                1 (3)              0 (0)                                                         1 (17)
  7b                                                     Explanation of any interim analyses and stopping guidelines, whenever applicable                                         0 (0)                                                                                                                                                                                              0 (0)              0 (0)                                                         
  Sequence generation                                    8a                                                                                                                       Method used to generate the random allocation sequence                                                                                                                                             21 (70)            18 (75)                                                       3 (50)
  8b                                                     Type of randomization and details of any restrictions (e.g., blocking and block size)                                    3 (10)                                                                                                                                                                                             0 (0)              3 (50)[\*](#tfn5-medscimonit-24-2946){ref-type="table-fn"}    
  Allocation concealment                                 9                                                                                                                        Mechanism used to implement the random allocation sequence (e.g., sequentially numbered containers) and description of any steps taken to conceal the sequence until interventions were assigned   4 (13)             0 (0)                                                         4 (67)[\*](#tfn5-medscimonit-24-2946){ref-type="table-fn"}
  Implementation                                         10                                                                                                                       Individuals that generated the random allocation sequence, enrolled participants, and assigned participants to interventions                                                                       1 (3)              0 (0)                                                         1 (17)
  Blinding                                               11a                                                                                                                      The group that was blinded after assignment to interventions (e.g. participants, care providers, those assessing outcomes) and the protocol of blinding, if performed                              6 (20)             0 (0)                                                         6 (100)[\*](#tfn5-medscimonit-24-2946){ref-type="table-fn"}
  11b                                                    If relevant, description of the similarity of interventions                                                              0 (0)                                                                                                                                                                                              0 (0)              0 (0)                                                         
  Statistical methods                                    12a                                                                                                                      Statistical methods used to compare groups for primary and secondary outcomes                                                                                                                      23 (77)            17 (71)                                                       6 (100)
  12b                                                    Methods for additional analyses, such as subgroup analyses and adjusted analyses                                         3 (10)                                                                                                                                                                                             1 (4)              2 (33)                                                        
  Participant flow (A diagram is strongly recommended)   13a                                                                                                                      The number of participants that were randomly assigned, received intended treatment, and were analyzed for the primary outcome are shown for each group                                            3 (10)             1 (4)                                                         2 (33)
  13b                                                    The number of participants that were lost or excluded after randomization and the reasons                                2 (13)                                                                                                                                                                                             0 (0)              2 (33)[\*](#tfn5-medscimonit-24-2946){ref-type="table-fn"}    
  Recruitment                                            14a                                                                                                                      Dates defining the periods of recruitment and follow-up                                                                                                                                            19 (63)            15 (63)                                                       4 (67)
  14b                                                    Reasons for ending or stopping the trial                                                                                 0 (0)                                                                                                                                                                                              0 (0)              0 (0)                                                         
  Baseline data                                          15                                                                                                                       A table showing baseline demographic and clinical characteristics for each group                                                                                                                   14 (47)            8 (33)                                                        6 (100)[\*](#tfn5-medscimonit-24-2946){ref-type="table-fn"}
  Numbers analyzed                                       16                                                                                                                       For each group, the number of participants (denominator) included in each analysis and if the analysis was performed as originally assigned                                                        3 (10)             1 (4%)                                                        2 (33)
  Outcomes and estimation                                17a                                                                                                                      For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (e.g., 95% confidence interval)                                                    29 (97)            23 (96)                                                       6 (100)
  17b                                                    For binary outcomes, presentation of both absolute and relative effect sizes is recommended                              30 (100)                                                                                                                                                                                           24 (100)           6 (100)                                                       
  Ancillary analyses                                     18                                                                                                                       Results of any other analyses performed, such as subgroup and adjusted analyses; distinguishing pre-specified from exploratory analyses                                                            0 (0)              0 (0)                                                         0 (0)
  Harms                                                  19                                                                                                                       All important harms or unintended adverse effects in each group; for specific guidance see CONSORT for Harms[\#](#tfn6-medscimonit-24-2946){ref-type="table-fn"}                                   8 (27)             3 (13)                                                        5 (83)[\*](#tfn5-medscimonit-24-2946){ref-type="table-fn"}

Indicate a significant difference with the studies published in Chinese journals;

CONSORT for harms can be seen on *<http://www.consort-statement.org/checklists/view/32--consort-2010/116-harms>*.

###### 

STRICTA assessment of the reporting characteristics of included studies (N=30; 24 studies from Chinese journals; 6 studies from English journals).

  Section/ topic                        Item                                                                                                                                                                     Description                                                                                                                                            Positive studies   Positive Chinese journals                                    Positive English journals
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------ ------------------------------------------------------------ ------------------------------------------------------------
  Acupuncture rationale                 1a                                                                                                                                                                       Style of acupuncture (e.g. Traditional Chinese Medicine, Japanese, Korean, Western medical, Five Element, ear acupuncture, etc)                        30 (100)           24 (100%)                                                    6 (100%)
  1b                                    Reasoning for treatment provided, historical context, literature sources, and/or consensus methods, with references provided wherever necessary                          9 (30)                                                                                                                                                 5 (21)             4 (67)[\*](#tfn7-medscimonit-24-2946){ref-type="table-fn"}   
  1c                                    Extent to which treatment varied                                                                                                                                         2 (7)                                                                                                                                                  0 (0)              2 (33)[\*](#tfn7-medscimonit-24-2946){ref-type="table-fn"}   
  Details of needling                   2a                                                                                                                                                                       Number of needle insertions per subject per session (mean and range wherever relevant)                                                                 23 (77)            20 (83)                                                      3 (50)
  2b                                    Names (or location if no standard name) of points used (uni/bilateral)                                                                                                   30 (100)                                                                                                                                               24 (24)            6 (100)                                                      
  2c                                    Depth of insertion, based on a specified unit of measurement or a particular tissue level                                                                                20 (67)                                                                                                                                                15 (63)            5 (83)                                                       
  2d                                    Response sought (e.g. de qi or muscle twitch response)                                                                                                                   23 (77)                                                                                                                                                17 (71)            6 (100)                                                      
  2e                                    Needle stimulation (e.g. manual, electrical)                                                                                                                             29 (97)                                                                                                                                                23 (96)            6 (100)                                                      
  2f                                    Needle retention time                                                                                                                                                    29 (97)                                                                                                                                                23 (96)            6 (100)                                                      
  2g                                    Needle type (diameter, length, and manufacturer or material)                                                                                                             22 (73)                                                                                                                                                16 (67)            6 (100)                                                      
  Treatment regimen                     3a                                                                                                                                                                       Number of treatment sessions                                                                                                                           30 (100)           24 (100)                                                     6 (100)
  3b                                    Frequency and duration of treatment sessions                                                                                                                             30 (100)                                                                                                                                               24 (100)           6 (100)                                                      
  Other components of treatment         4a                                                                                                                                                                       Details of other interventions administered to the acupuncture group (e.g. moxibustion, cupping, herbs, exercises, lifestyle modification advice)      10 (33)            5 (21)                                                       5 (83)[\*](#tfn7-medscimonit-24-2946){ref-type="table-fn"}
  4b                                    Setting and context of treatment, including instructions to practitioners, and information to patients                                                                   1 (3)                                                                                                                                                  0 (0)              1 (17)                                                       
  Practitioner background               5                                                                                                                                                                        Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice and other relevant experience)   1 (3)              0 (0)                                                        1 (17)
  Control or comparator interventions   6a                                                                                                                                                                       Rationale for the control or comparator in the context of the research question and sources justifying the choice                                      2 (7)              0 (0)                                                        2 (33)[\*](#tfn7-medscimonit-24-2946){ref-type="table-fn"}
  6b                                    Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like control is used, provide details as for Items 1 to 3 above   28 (93)                                                                                                                                                22 (92)            6 (100)                                                      

Indicates a significant difference with the studies published in Chinese journals.

###### 

Sensitivity analysis -- systolic pressure.

  Study omitted                                                                        Estimate   95% Confidence interval (CI)   
  ------------------------------------------------------------------------------------ ---------- ------------------------------ -------
  **Acupuncture *vs.* medication**                                                                                               
  Chen BG 2006                                                                         1.92       −1.41                          5.25
  Chen NY 2010                                                                         0.27       −1.79                          2.33
  Chen YF 2000                                                                         1.90       −0.93                          4.72
  Tian L 2008                                                                          2.15       −0.97                          5.27
  Wu YR 2011                                                                           0.84       −1.88                          3.55
  Xie B 2014                                                                           1.13       −1.83                          4.10
  Xing H 2016                                                                          1.43       −1.59                          4.45
  Zhang Y 2012                                                                         1.94       −1.23                          5.10
  **Acupuncture *vs.* sham acupuncture**                                                                                         
  Choi WJ 2015                                                                         −2.13      −7.63                          3.36
  Kim HM 2012                                                                          5.05       1.76                           8.33
  Zheng Y 2016                                                                         1.53       −7.03                          10.09
  **Acupuncture plus lifestyle *vs.* lifestyle**                                                                                 
  Sun J 2009                                                                           12.09      9.14                           15.04
  WU XM 2015                                                                           10.01      2.77                           17.25
  Zhao DJ 2003                                                                         8.58       4.32                           12.83
  **Acupuncture plus antihypertensive *vs.* antihypertensive**                                                                   
  Huang F 2007                                                                         10.83      3.38                           18.27
  Luo H 2015                                                                           11.36      5.20                           17.53
  Shen ZK 2007                                                                         7.20       4.19                           10.22
  Zhang YB 2011                                                                        9.23       0.99                           17.47
  Zhang YL 2005                                                                        10.24      2.56                           17.91
  **Acupuncture plus antihypertensive *vs.* sham acupuncture plus antihypertensive**                                             
  Flachskampf FA 2007                                                                  10.80      6.41                           15.19
  Yin C 2013                                                                           7.00       2.88                           11.12
  **Electroacupuncture *vs.* antihypertensive**                                                                                  
  Ma ZY 2011                                                                           2.97       −4.51                          10.46
  Wan WJ 2009                                                                          2.92       −4.67                          10.53
  Yang DH 2010                                                                         −0.81      −4.61                          2.99

###### 

Sensitivity analysis -- diastolic pressure.

  Study omitted                                                                        Estimate   95% Confidence interval (CI)   
  ------------------------------------------------------------------------------------ ---------- ------------------------------ -------
  **Acupuncture *vs.* medication**                                                                                               
  Chen BG 2006                                                                         2.21       −1.25                          5.67
  Chen NY 2010                                                                         1.83       −1.07                          4.72
  Chen YF 2000                                                                         2.80       0.14                           5.46
  Tian L 2008                                                                          2.53       −0.53                          5.59
  Wu YR 2011                                                                           2.36       −0.61                          5.32
  Xie B 2014                                                                           0.61       −0.95                          2.16
  Xing H 2016                                                                          1.75       −1.05                          4.55
  Zhang Y 2012                                                                         2.40       −0.85                          5.65
  **Acupuncture *vs.* sham acupuncture**                                                                                         
  Choi WJ 2015                                                                         −1.79      −5.48                          1.91
  Kim HM 2012                                                                          −0.44      −5.44                          4.57
  Zheng Y 2016                                                                         0.70       −1.70                          3.10
  **Acupuncture plus lifestyle *vs.* lifestyle**                                                                                 
  Sun J 2009                                                                           7.67       2.65                           12.69
  WU XM 2015                                                                           3.66       0.15                           7.18
  Zhao DJ 2003                                                                         6.01       −2.55                          14.58
  **Acupuncture plus antihypertensive *vs.* antihypertensive**                                                                   
  Huang F 2007                                                                         8.69       5.32                           12.07
  Luo H 2015                                                                           8.16       3.78                           12.54
  Shen ZK 2007                                                                         7.18       2.93                           11.44
  Zhang YB 2011                                                                        6.57       3.87                           9.28
  Zhang YL 2005                                                                        8.51       4.99                           12.03
  **Acupuncture plus antihypertensive *vs.* sham acupuncture plus antihypertensive**                                             
  Flachskampf FA 2007                                                                  5.80       2.77                           8.83
  Yin C 2013                                                                           3.00       −0.18                          6.18
  **Electroacupuncture *vs.* antihypertensive**                                                                                  
  Ma ZY 2011                                                                           −1.86      −7.14                          3.41
  Wan WJ 2009                                                                          −1.07      −3.55                          1.42
  Yang DH 2010                                                                         −2.72      −5.13                          −0.31

###### 

Sensitivity analysis -- efficacy rate.

  Study omitted                                                  Estimate   95% Confidence interval (CI)   
  -------------------------------------------------------------- ---------- ------------------------------ ------
  **Acupuncture *vs.* antihypertensive**                                                                   
  Chen BG 2006                                                   1.12       0.97                           1.30
  Chen NY 2010                                                   1.14       0.96                           1.34
  Chen Q 2011                                                    1.12       0.97                           1.28
  Chen YF 2000                                                   1.19       1.06                           1.35
  Tian L 2008                                                    1.17       1.01                           1.36
  Wu YR 2011                                                     1.11       0.96                           1.28
  Xie B 2014                                                     1.17       0.99                           1.37
  Xing H 2016                                                    1.14       1.00                           1.31
  Zhang ZH 2004                                                  1.13       0.97                           1.30
  **Acupuncture plus lifemodification *vs.* lifemodification**                                             
  Su J 2009                                                      1.29       1.04                           1.61
  Wu XM 2015                                                     1.14       0.97                           1.35
  **Acupuncture plus antihypertensive *vs.* antihypertensive**                                             
  Chen J 2010                                                    1.17       1.08                           1.27
  Cui JK 2013                                                    1.18       1.08                           1.28
  Huang F 2007                                                   1.19       1.09                           1.29
  Luo H 2015                                                     1.16       1.06                           1.27
  Shen ZK 2007                                                   1.18       1.08                           1.29
  Zhang YB 2011                                                  1.17       1.07                           1.27
  Zhang YL 2005                                                  1.17       1.07                           1.27
  **Electroacupuncture *vs.* antihypertensive**                                                            
  Ma ZY 2011                                                     0.95       0.67                           1.34
  Wan WJ 2009                                                    0.93       0.71                           1.22

###### 

List and details of reviews (including this review) analyzing acupuncture therapy for hypertension.

  Author/year             Language   Clinical characteristics                                                                                                                                                          No. of trials              Search date      Primary outcomes                                                                            Subgroup analysis
  ----------------------- ---------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ---------------- ------------------------------------------------------------------------------------------- -------------------------------------------------------------
  Zhang et al., 2013      Chinese    AC *vs.* medication; AC *vs.* SA; AC plus medication *vs.* medication                                                                                                             11                         October 2012     SBP and DBP change magnitude/adverse effect                                                 Mainly based on different interventions
  Guo W et al., 2013      Chinese    AC plus medication *vs.* medication                                                                                                                                               10                         May 31, 2012     SBP and DBP after intervention/efficacy rate/adverse effect                                 Not performed
  Lee H et al., 2009      English    AC plus medication *vs.* SA plus medication; AC *vs.* SA; AC plus medication vs. medication; AC *vs.* medication                                                                  11 (3 in meta-analysis)    June, 2007       SBP and DBP change magnitude/adverse effect                                                 Not performed
  Li DZ et al., 2014      English    AC *vs.* SA; AC plus medication *vs.* SA plus medication                                                                                                                          4                          November, 2012   SBP and DBP change magnitude/adverse effect                                                 Mainly based on different interventions
  Wang J et al., 2013     English    AC *vs.* SA; AC plus medication *vs.* medication; AC *vs.* medication; AC plus medication *vs.* SA plus medication; AC plus lifestyle modification *vs.* lifestyle modification   35 (24 in meta-analysis)   January, 2013    SBP and DBP change magnitude/adverse effect                                                 Mainly based on different interventions
  Zhang YJ et al., 2013   Chinese    AC *vs.* medication; AC plus medication *vs.* medication                                                                                                                          13                         July, 2013       SBP and DBP after intervention/efficacy rate/adverse effect                                 Not performed
  Zhao XF et al., 2015    English    AC plus medication *vs.* medication; AC *vs.* medication; AC plus medication *vs.* SA plus medication; AC plus lifestyle modification *vs.* lifestyle modification                23                         April 13, 2014   SBP and DBP change magnitude/SBP and DBP after intervention/efficacy rate/adverse effect/   Mainly based on different interventions
  The current review      English    AC *vs.* medication; AC *vs.* SA; AC *vs.* no-treatment; AC plus medication *vs.* medication; AC plus medication *vs.* SA plus medication                                         31                         April 30, 2017   SBP and DBP change magnitude/efficacy rate/adverse effect                                   Mainly based on different classes of antihypertensive drugs

AC -- acupuncture; SA -- sham acupuncture.

###### 

Main findings of previous reviews that analyzed acupuncture therapy outcomes in hypertension patients.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/year             Comparison                                                    No. of trials   Outcomes[\*](#tfn10-medscimonit-24-2946){ref-type="table-fn"},[\*\*](#tfn11-medscimonit-24-2946){ref-type="table-fn"}                                  
  ----------------------- ------------------------------------------------------------- --------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------ ------------------------
  Guo et al., 2013        AC plus medication *vs.* medication                           4               SBP: −8.35 (−10.89, −5.81)\                                                                                             Not reported                   OR: 5.23 (3.24, 8.44)
                                                                                                        DBP: −5.25 (−11.19, −.69)                                                                                                                              

  Lee H et al., 2009      AC *vs.* SA                                                   3               Not reported                                                                                                            SBP: −5 (−12, 1)\              Not reported
                                                                                                                                                                                                                                DBP: −3 (−6, 0)                

  Lee H et al., 2009      AC plus medication *vs.* SA plus medication                   2               Not reported                                                                                                            SBP: −8 (−10, −5)\             Not reported
                                                                                                                                                                                                                                DBP: −4 (−6, −2)               

  Li DZ et al., 2014      AC *vs.* SA                                                   2               Not reported                                                                                                            SBP: 1.33 (−0.25, 5.16)\       Not reported
                                                                                                                                                                                                                                DBP: −0.18 (−3.98, 3.62)       

  Li DZ et al., 2014      AC plus medication *vs.* SA plus medication                   2               Not reported                                                                                                            SBP: −8.58 (−10.13, −7.13)\    Not reported
                                                                                                                                                                                                                                DBP: −2.82 (−5.22, −0.43)      

  Wang J et al., 2013     AC *vs.* medication                                           11              Not reported                                                                                                            SBP: −0.77 (−3.89, 2.35)\      Not reported
                                                                                                                                                                                                                                DBP: 0. 1 (−1.6, 1.79)         

  Wang J et al. 2013      AC plus medication *vs.* medication                           7               Not reported                                                                                                            SBP: −10.2 (−14, −6.4)\        Not reported
                                                                                                                                                                                                                                DBP: −4.34 (−6.79, −1.9)       

  Wang J et al. 2013      AC *vs.* SA                                                   3               Not reported                                                                                                            SBP: 0.26 (−2.4, 2.91)\        Not reported
                                                                                                                                                                                                                                DBP: −1.04 (−2.56, 0.47)       

  Wang J et al., 2013     AC plus medication *vs.* SA plus medication                   2               Not reported                                                                                                            SBP: −7.74 (−10.43, −4.51)\    Not reported
                                                                                                                                                                                                                                DBP: −4.22 (−6.26, −2.18)      

  Wang J et al., 2013     AC plus lifestyle modification *vs.* lifestyle modification   1               Not reported                                                                                                            SBP: −13.5 (−15.06, −11.94)\   Not reported
                                                                                                                                                                                                                                DBP: −5.25 (−6.01, −4.49)      

  Zhang YJ et al., 2013   AC *vs.* medication                                           7               SBP: −3.26 (−7.98, 1.46)\                                                                                               Not reported                   OR: 0.95 (0.45,2)
                                                                                                        DBP: −2.17 (−5.02, 0.68)                                                                                                                               

  Zhang YJ et al., 2013   AC plus medication *vs.* medication                           4               SBP: −9.5 (−13.66, −5.34)\                                                                                              Not reported                   OR: 5.13 (2.6,10.11)
                                                                                                        DBP: −0.16 (−2.52, 2.19)                                                                                                                               

  Zhao XF et al., 2015    AC *vs.* medication                                           7               SBP: −0.56 (−3.02, 1.89)\                                                                                               Not reported                   OR: 1.14 (0.7, 1.85)
                                                                                                        DBP: −1.01 (−2.26, 0.24)                                                                                                                               

  Zhao XF et al., 2015    AC plus medication *vs.* medication                           3               SBP: −9.04 (−20.11,2.02)\                                                                                               Not reported                   OR: 4.19 (1.65, 10.67)
                                                                                                        DBP: −2.87 (−8.45, 2.72)                                                                                                                               

  Zhao XF et al., 2015    AC plus lifestyle modification *vs.* lifestyle modification   1               SBP: −10.53 (−27.52, 6.46)\                                                                                             Not reported                   Not reported
                                                                                                        DBP: −7.52 (−15.06, 0.02)                                                                                                                              

  Zhao XF et al., 2015    AC *vs.* SA                                                   2               Not reported                                                                                                            SBP: 0.3 (−0.27, 0.88)\        Not reported
                                                                                                                                                                                                                                DBP: −1.4 (−2.37, −0.44)       

  Zhao XF et al., 2015    AC plus medication *vs.* SA plus medication                   2               Not reported                                                                                                            SBP: −7.47 (−10.43, −4.51)\    Not reported
                                                                                                                                                                                                                                DBP: −4.22 (−6.26, −2.18)      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AC -- acupuncture; SA -- sham acupuncture; No. -- number.

Effect size was presented with mean difference (MD, 95% confidence interval \[lower limit, upper limit\]) in continuous variables or risk ratio or odds ratio (RR or OR, 95% confidence interval \[lower limit, upper limit\]) in dichotomous variables;

Lower is better for continuous variables.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
